Details

Autor(en) / Beteiligte

• Chootipongchaivat, Sarocha
• van Ravesteyn, Nicolien T
• Li, Xiaoxue
• Huang, Hui
• Weedon-Fekjær, Harald
• Ryser, Marc D
• Weaver, Donald L
• Burnside, Elizabeth S
• Heckman-Stoddard, Brandy M
• de Koning, Harry J
• Lee, Sandra J

Titel

Modeling the natural history of ductal carcinoma in situ based on population data

Ist Teil von

• Breast cancer research : BCR, 2020-05, Vol.22 (1), p.53-53, Article 53

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2020

Quelle

Springer Nature - Complete Springer Journals

Beschreibungen/Notizen

• The incidence of ductal carcinoma in situ (DCIS) has increased substantially since the introduction of mammography screening. Nevertheless, little is known about the natural history of preclinical DCIS in the absence of biopsy or complete excision. Two well-established population models evaluated six possible DCIS natural history submodels. The submodels assumed 30%, 50%, or 80% of breast lesions progress from undetectable DCIS to preclinical screen-detectable DCIS; each model additionally allowed or prohibited DCIS regression. Preclinical screen-detectable DCIS could also progress to clinical DCIS or invasive breast cancer (IBC). Applying US population screening dissemination patterns, the models projected age-specific DCIS and IBC incidence that were compared to Surveillance, Epidemiology, and End Results data. Models estimated mean sojourn time (MST) in the preclinical screen-detectable DCIS state, overdiagnosis, and the risk of progression from preclinical screen-detectable DCIS. Without biopsy and surgical excision, the majority of DCIS (64-100%) in the preclinical screen-detectable state progressed to IBC in submodels assuming no DCIS regression (36-100% in submodels allowing for DCIS regression). DCIS overdiagnosis differed substantially between models and submodels, 3.1-65.8%. IBC overdiagnosis ranged 1.3-2.4%. Submodels assuming DCIS regression resulted in a higher DCIS overdiagnosis than submodels without DCIS regression. MST for progressive DCIS varied between 0.2 and 2.5 years. Our findings suggest that the majority of screen-detectable but unbiopsied preclinical DCIS lesions progress to IBC and that the MST is relatively short. Nevertheless, due to the heterogeneity of DCIS, more research is needed to understand the progression of DCIS by grades and molecular subtypes.